Academic literature on the topic 'F. Hoffman-La Roche AG'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'F. Hoffman-La Roche AG.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "F. Hoffman-La Roche AG"
Pott, Christiane, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, et al. "Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients." Blood 132, Supplement 1 (November 29, 2018): 396. http://dx.doi.org/10.1182/blood-2018-99-115930.
Full textNishimura, Jun-ichi, Antoine Soubret, Simon Buatois, Jean-Eric Charoin, Sasha Sreckovic, Christoph Bucher, Jules Hernández-Sánchez, et al. "An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial." Blood 136, Supplement 1 (November 5, 2020): 2–3. http://dx.doi.org/10.1182/blood-2020-136265.
Full textSchmidt, Christian, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Sascha Haubner, Christian Buske, et al. "Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)." Blood 132, Supplement 1 (November 29, 2018): 448. http://dx.doi.org/10.1182/blood-2018-99-111692.
Full textVersmold, Katharina, Ferras Alashkar, Carina Raiser, Richard Ofori-Asenso, Tao Xu, Yutong Liu, Pablo Katz, Aijing Shang, and Alexander Roeth. "Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis." Blood 138, Supplement 1 (November 5, 2021): 4314. http://dx.doi.org/10.1182/blood-2021-147162.
Full textLi, Chi-Chung, Brendan Bender, Shen Yin, Zao Li, Cindy Zhang, Genevive Hernandez, Antonia Kwan, et al. "Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 1285. http://dx.doi.org/10.1182/blood-2019-123961.
Full textAlig, Stefan, Alessandro Pastore, Vindi Jurinovic, Sarah Häbe, Deepak Bararia, Verena Passerini, William Keay, et al. "Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial." Blood 132, Supplement 1 (November 29, 2018): 4096. http://dx.doi.org/10.1182/blood-2018-99-118000.
Full textGrether, Uwe, and Julie Blaising. "MAGL inhibition: A novel treatment option for combating inflammatory disease?" Open Access Government 41, no. 1 (January 19, 2024): 48–49. http://dx.doi.org/10.56367/oag-041-11209.
Full textPhillips, Tycel J., Adam J. Olszewski, Javier Munoz, Tae Min Kim, Dok Hyun Yoon, Richard Greil, Jason Westin, et al. "Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 37–38. http://dx.doi.org/10.1182/blood-2020-136295.
Full textNégrier, Claude, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, et al. "Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study." Blood 138, Supplement 1 (November 5, 2021): 343. http://dx.doi.org/10.1182/blood-2021-146009.
Full textKhair, Kate, Francis Nissen, Mariabeth Silkey, Tom Burke, Aijing Shang, Martynas Aizenas, Oliver Meier, Jamie O'Hara, and Declan Noone. "Effect of Moderate and Severe Hemophilia a on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis." Blood 136, Supplement 1 (November 5, 2020): 43–45. http://dx.doi.org/10.1182/blood-2020-134658.
Full textDissertations / Theses on the topic "F. Hoffman-La Roche AG"
Bertram, Florian. "The strategic management of innovation : resource allocation and the creation and establishment of new and uncertain opportunities /." [S.l.] : [s.n.], 2009. http://aleph.unisg.ch/hsgscan/hm00264350.pdf.
Full textBartl, Daniel. "The strategic management of coherence : how to keep a firm on track under uncertainty /." [S.l. : s.n.], 2008. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=017049650&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.
Full textMatheis, Sebastian. "Preparation of a Class A certification in the field of pharmaceutical packaging through mapping and optimization of business processes and implementation of the Oliver Wight Class A Behaviors for Business Excellence." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-227771.
Full textBooks on the topic "F. Hoffman-La Roche AG"
1890-1969, Spreng Robert, ed. Robert Spreng und seine Fotodokumentation zu O.R. Salvisbergs Verwaltungsgebäude der F. Hoffmann-La Roche AG, Basel: Robert Spreng and his photographs of O.R. Salvisberg's executive office building for F. Hoffmann-La Roche Ltd in Basel. Basel: Editiones Roche, 2001.
Find full textStraumann, Lukas. Schweizer Chemieunternehmen im "Dritten Reich". Zürich: Chronos, 2001.
Find full textBook chapters on the topic "F. Hoffman-La Roche AG"
Kres, Michael. "Alexander von Faber, F. Hoffmann-La Roche AG." In Mutmacher: Unternehmen stärken durch mutige Führung, 157–63. Wiesbaden: Springer Fachmedien Wiesbaden, 2014. http://dx.doi.org/10.1007/978-3-658-06098-5_20.
Full textKres, Michael. "Alexander von Faber, F. Hoffmann-La Roche AG." In Mutmacher: Unternehmen stärken durch mutige Führung, 141–47. Wiesbaden: Springer Fachmedien Wiesbaden, 2017. http://dx.doi.org/10.1007/978-3-658-14288-9_15.
Full textKres, Michael. "Alexander von Faber, F. Hoffmann-La Roche AG." In Mutmacher: Unternehmen stärken durch mutige Führung, 145–51. Wiesbaden: Springer Fachmedien Wiesbaden, 2013. http://dx.doi.org/10.1007/978-3-658-02144-3_18.
Full textTaber, Douglass F. "Developments in Flow Chemistry." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0017.
Full text